Arca
Skip to content
Tools
Tools

Proteinuria

Drug research and approvals for proteinuria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 49 studies of proteinuria are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 9 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 49
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 9
  • EU medicines: 0

Recruiting now

Newest posted first, of 49 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

  • LosartanType-1 angiotensin II receptor antagonist

Phase 3 9

Phase 2 4

Phase 1 or earlier 1

How its trials ended

195 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 47 whose ending is known, 38% met their primary endpoint, 6% missed it and 55% stopped early.

  • Completed, result not reported8443%
  • Status unknown4021%
  • Ongoing2412%
  • Met its primary endpoint189%
  • Stopped: other or unclear189%
  • Stopped: enrollment or feasibility84%
  • Missed its primary endpoint32%

FDA orphan designations

Approved first, then open designations, newest first
Nov 13, 2026GazyvaTreatment of adult patients with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuriaGenentech, Inc., A Member of the Roche GroupApproved
Aug 20, 2026EmpaveliTreatment of adult and pediatric patients aged 12 years and older with primary immune-complex membranoproliferative glomerulonephritis…Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc.Approved
Aug 20, 2026EmpaveliTreatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria and the loss of…Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc.Approved
Apr 13, 2026FilspariTo reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without…Travere Therapeutics, Inc.Approved
Jul 28, 2025EmpaveliTreatment of adult and pediatric patients aged 12 years and older with primary immune-complex membranoproliferative glomerulonephritis…Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc.Approved
Jul 28, 2025EmpaveliTreatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuriaApellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc.Approved
Mar 20, 2025FabhaltaTreatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuriaNovartis Pharmaceuticals CorporationApproved
Feb 17, 2023FilspariTo reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine…Travere Therapeutics, Inc.Approved
Dec 15, 2021TarpeyoTo reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine…Calliditas Therapeutics ABApproved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.